Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 478

1.

The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.

Deaton DN, Do Y, Holt J, Jeune MR, Kramer HF, Larkin AL, Orband-Miller LA, Peckham GE, Poole C, Price DJ, Schaller LT, Shen Y, Shewchuk LM, Stewart EL, Stuart JD, Thomson SA, Ward P, Wilson JW, Xu T, Guss JH, Musetti C, Rendina AR, Affleck K, Anders D, Hancock AP, Hobbs H, Hodgson ST, Hutchinson J, Leveridge MV, Nicholls H, Smith IED, Somers DO, Sneddon HF, Uddin S, Cleasby A, Mortenson PN, Richardson C, Saxty G.

Bioorg Med Chem. 2019 Feb 11. pii: S0968-0896(18)32008-X. doi: 10.1016/j.bmc.2019.02.017. [Epub ahead of print]

PMID:
30858025
2.

PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.

Tinworth CP, Lithgow H, Dittus L, Bassi ZI, Hughes SE, Muelbaier M, Dai H, Smith IED, Kerr WJ, Burley GA, Bantscheff M, Harling JD.

ACS Chem Biol. 2019 Mar 15;14(3):342-347. doi: 10.1021/acschembio.8b01094. Epub 2019 Feb 27.

PMID:
30807093
3.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

4.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

5.

De-escalating and escalating systemic therapy of early breast cancer.

Smith IE, Okines AFC.

Breast. 2017 Aug;34 Suppl 1:S5-S9. doi: 10.1016/j.breast.2017.06.019. Epub 2017 Jul 8. No abstract available.

PMID:
28694014
6.

Reply to R. Goncalves et al.

Smith IE.

J Clin Oncol. 2017 Aug 10;35(23):2719. doi: 10.1200/JCO.2017.73.2214. Epub 2017 Jun 5. No abstract available.

PMID:
28581885
7.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 2017 Jul;164(2):395-400. doi: 10.1007/s10549-017-4266-9. Epub 2017 Apr 26.

8.

Hospital outcomes and long-term survival after referral to a specialized weaning unit.

Davies MG, Quinnell TG, Oscroft NS, Clutterbuck SP, Shneerson JM, Smith IE.

Br J Anaesth. 2017 Apr 1;118(4):563-569. doi: 10.1093/bja/aex031.

9.

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.

Detre SI, Ashley S, Mohammed K, Smith IE, Powles TJ, Dowsett M.

Cancer Prev Res (Phila). 2017 Mar;10(3):171-176. doi: 10.1158/1940-6207.CAPR-16-0247-T. Epub 2017 Jan 18.

10.

Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cort├ęs J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.

PMID:
27831505
11.

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.

Klintman M, Buus R, Cheang MC, Sheri A, Smith IE, Dowsett M.

Clin Cancer Res. 2016 May 15;22(10):2405-16. doi: 10.1158/1078-0432.CCR-15-1488.

12.

Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.

Kordbacheh T, Law WY, Smith IE.

Breast. 2016 Apr;26:54-8. doi: 10.1016/j.breast.2015.11.005. Epub 2016 Jan 22. Review.

PMID:
27017242
13.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
14.

Characterization and quantification of suspended sediment sources to the Manawatu River, New Zealand.

Vale SS, Fuller IC, Procter JN, Basher LR, Smith IE.

Sci Total Environ. 2016 Feb 1;543(Pt A):171-86. doi: 10.1016/j.scitotenv.2015.11.003. Epub 2015 Nov 12.

PMID:
26580740
15.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

16.

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE.

Breast. 2015 Dec;24(6):751-7. doi: 10.1016/j.breast.2015.09.008. Epub 2015 Oct 9.

PMID:
26456898
17.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
18.

Management of breast cancer in older and frail patients.

Smith IE, Fribbens C.

Breast. 2015 Nov;24 Suppl 2:S159-62. doi: 10.1016/j.breast.2015.07.037. Epub 2015 Aug 21.

PMID:
26303987
19.

Catalytic in vivo protein knockdown by small-molecule PROTACs.

Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM.

Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858. Epub 2015 Jun 10.

20.

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM.

ACS Chem Biol. 2015 Aug 21;10(8):1831-7. doi: 10.1021/acschembio.5b00442. Epub 2015 Jun 23.

Supplemental Content

Loading ...
Support Center